{
    "clinical_study": {
        "@rank": "21671", 
        "acronym": "ACTION", 
        "arm_group": [
            {
                "arm_group_label": "Arsenic trioxide TACE", 
                "arm_group_type": "Active Comparator", 
                "description": "Arsenic trioxide TACE: arsenic trioxide powder 20mg dissolved in lipiodol(the dosage of lipiodol is decided according to the volume of the target lesion)is used for transcatheter arterial chemoembolization(TACE). TACE will be repeated after 4~6 weeks if it is necessary according to the assessment from imaging modalities."
            }, 
            {
                "arm_group_label": "Arsenic trioxide TACE+IV", 
                "arm_group_type": "Experimental", 
                "description": "Arsenic trioxide TACE: arsenic trioxide powder 20mg dissolved in lipiodol(the dosage of lipiodol is decided according to the volume of the target lesion)is used for transcatheter arterial chemoembolization(TACE). TACE will be repeated after 4~6 weeks if it is necessary according to the assessment from imaging modalities.\nArsenic trioxide intravenous infusion: arsenic trioxide powder 0.15mg/Kg/d(maxim 10mg/d) dissolved in 250ml 0.9% sodium chloride solution is used for intravenous infusion.Every course will last for 3 weeks and the next course will be continued after 1 week suspension.Intravenous infusion will be suspended 3 days before and 7~14 days after TACE."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether compared with arsenic trioxide TACE alone,\n      arsenic trioxide TACE and intravenous administration could further prolong the overall\n      survival."
        }, 
        "brief_title": "Arsenic Trioxide TACE and Intravenous Administration in Unresectable Hepatocellular Carcinoma", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Carcinoma, Hepatocellular", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Hepatocellular"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Having signed informed consent;\n\n          -  Histological or clinical diagnosis of hepatocellular carcinoma\uff08HCC\uff09;\n\n          -  The target lesion should had at least one diameter line available for measurement,\n             with the maximum diameter \u22655cm and \u226410cm\uff1b\n\n          -  Barcelona Clinic Liver Cancer staging B or C;\n\n          -  Child-Pugh liver function class: score\u22647\uff1b\n\n          -  Eastern Cooperative Oncology Group performance 0 or 1;\n\n          -  At least 12 weeks life expectancy;\n\n          -  Never received systemic treatment, such as oral molecularly targeted drugs and\n             systemic chemotherapy;\n\n          -  Be able to abide by the treatment and follow-up plan\uff1b\n\n          -  Adequate results for laboratory tests, including:\n\n               1. Neutrophil count\u22651.5\u00d7109/L, platelet count\u226560\u00d7109 /L; hemoglobin\u226585g/L;\n\n               2. Total bilirubin\u226451.3 \u03bcmol/L, albumin\u226528 g/L,and alanine aminotransferase and\n                  aspartate aminotransferase\u22645 times the upper limit of the normal range;\n\n               3. Amylase and lipase\u22641.5 times the upper limit of the normal range\n\n               4. Serum creatinine\u226420 g/L\n\n               5. Prothrombin time international normalized ratio \u22641.7; or prothrombin\n                  time\u22644seconds above control;\n\n               6. Left ventricular ejection fraction\u226550% according to two-dimensional\n                  echocardiography;\n\n          -  Contraception: during the trail and 12 weeks after the withdrawal, female of\n             childbearing age (WOCBP), WOCBP whose male partners receive study drug or male must\n             use appropriate contraceptive to avoid pregnancy;\n\n        Exclusion Criteria:\n\n          -  Disease should be excluded:\n\n               1. CT / MRI showed diffuse lesions;\n\n               2. Extrahepatic metastasis (metastasis in lungs not included);\n\n               3. Invasion in the main portal vein / vena cava or other major vascular;\n\n               4. Previous shunt surgery;\n\n               5. PreviousTACE or transarterial embolization for HCC, unless there is a untreated\n                  lesion;\n\n               6. Hepatic encephalopathy in the past or present;\n\n               7. Current ascites requiring treatment;\n\n          -  Medical history and concomitant diseases:\n\n               1. Previous or current cancer other than HCC, unless it is cervical carcinoma in\n                  situ, treated basal cell carcinoma, superficial bladder tumors (Ta, Tis and T1).\n                  Cancer having received curative treatment 5 years ago will not be excluded;\n\n               2. Disease history in the cardiovascular system as the following:\n\n             (a)Uncontrolled hypertension\uff1b(b)Congestive heart failure in New York Heart\n             Association grade 3 or 4; (c)Active coronary artery disease within 12 months,\n             unstable angina or newly diagnosed angina/myocardial infarction;(d)Arrhythmia\n             requiring drugs other than \u03b2-blockers and digoxin;(e)Valvular heart disease \u2265 CTCAE\n             grade 2\uff1b c) Corrected QT interval (Fridericia)> 450 ms confirmed by 2 ECGs in a row\n             d) Thrombotic or embolic events within 6 months, e) Gastrointestinal bleeding within\n             6 months; f) Unstable and / or active stomach ulcer within 6 months, unless\n             gastroscopy showed it to be fully recovered; g) Variceal bleeding within 6 months; h)\n             Unhealed wound or ulcer, fracture within 3 months; i) Major surgery, open biopsy, or\n             severe trauma within 3 weeks; j) History of organ transplant or subjects in the\n             transplant waiting list; k) Uncontrolled abnormal thyroid function; l) HIV infection;\n             m) Active or untreated hepatitis B;\n\n          -  laboratory tests unsuitable for the enrollment\uff1a\n\n               1. Hyponatremia, serum sodium <130 mmol / L\uff1b\n\n               2. Hypokalemia, serum potassium <3.5 mmol / L\uff1b\n\n          -  Allergic reactions to arsenic trioxide and any other drugs used in this trail;\n\n          -  Forbidden therapies and/or drugs:\n\n               1. Condensation treatment (e.g., warfarin or heparin);\n\n               2. Chronic antiplatelet therapy (Aspirin \u2265 300 mg / day; clopidogrel \u2265 75 mg /\n                  day);\n\n               3. Radiotherapy within 4 weeks;"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "258", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01861912", 
            "org_study_id": "GDREC2013109H(R1)"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Arsenic trioxide TACE", 
                    "Arsenic trioxide TACE+IV"
                ], 
                "description": "Arsenic trioxide powder 20mg dissolved in lipiodol(the dosage of lipiodol is decided according to the volume of the target lesion)is used for transcatheter arterial chemoembolization(TACE). TACE will be repeated after 4~6 weeks if it is necessary according to the assessment from imaging modalities", 
                "intervention_name": "Arsenic trioxide TACE", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Arsenic trioxide TACE+IV", 
                "description": "Arsenic trioxide intravenous infusion: arsenic trioxide powder 0.15mg/Kg/d(maxim 10mg/d) dissolved in 250ml 0.9%NaCl solution is used for intravenous infusion.Every course will last for 3 weeks and the next course will be continued after 1 week suspension.Intravenous infusion will be suspended 3 days before and 7~14 days after TACE.", 
                "intervention_name": "Arsenic trioxide intravenous infusion", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Arsenic trioxide TACE", 
                    "Arsenic trioxide TACE+IV"
                ], 
                "description": "Lipiodol is used to dissolve arsenic trioxide for TACE,with the dosage decided according to the volume of the target lesion.", 
                "intervention_name": "lipiodol", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Arsenic trioxide TACE+IV", 
                "description": "250ml NaCl solution is used to dissolve the arsenic trioxide for intravenous infusion.", 
                "intervention_name": "NaCl solution", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Arsenic trioxide", 
                "Ethiodized Oil"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Carcinoma, Hepatocellular", 
            "Arsenic trioxide"
        ], 
        "lastchanged_date": "June 4, 2013", 
        "number_of_arms": "2", 
        "official_title": "Arsenic Trioxide TACE and Intravenous Administration Compared With Arsenic Trioxide TACE Alone in Unresectable Hepatocellular Carcinoma: a Randomized, Parallel, Controlled, Multi-center Clinical Study", 
        "other_outcome": [
            {
                "description": "Extrahepatic metastasis rate is defined as the proportion of the extrahepatic metastasis for patients who were absent of extrahepatic metastasis at enrollment.", 
                "measure": "Extrahepatic Metastasis Rate", 
                "safety_issue": "No", 
                "time_frame": "From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years."
            }, 
            {
                "description": "Recurrence rate is defined as the proportion of the recurrence in the patients.", 
                "measure": "Recurrence Rate", 
                "safety_issue": "No", 
                "time_frame": "From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years."
            }
        ], 
        "overall_official": {
            "affiliation": "Guangdong General Hospital", 
            "last_name": "Ligong Lu, Doctor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Time to progression in our study is defined as the time from a patient's enrollment to the time for disease progression (according to Recist1.1).", 
            "measure": "Time to Progression", 
            "safety_issue": "No", 
            "time_frame": "From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01861912"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Guangdong General Hospital", 
            "investigator_full_name": "Ligong Lu", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Overall survival in our study is defined as the time from a patient's enrollment to the time for death.", 
                "measure": "Overall Survival", 
                "safety_issue": "No", 
                "time_frame": "From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years."
            }, 
            {
                "description": "Quality of life is assessed according to the FACT-Hep questionnaire.", 
                "measure": "Quality of Life", 
                "safety_issue": "Yes", 
                "time_frame": "From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years."
            }, 
            {
                "description": "Safety of our treatment plan will be assessed according to the Common Terminology Criteria for Adverse Events\uff08CTCAE\uff09 3.0", 
                "measure": "Safety", 
                "safety_issue": "Yes", 
                "time_frame": "From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years."
            }
        ], 
        "source": "Guangdong General Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Guangdong General Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}